Abiel is committed to R&D, production and marketing of innovative enzymes, synthesized by a patented genetic engineering process for regenerative medicine applications, and to R&D of new enzymes from biomarine resources, able to work also in low-temperature processes.
Abiel’s team is made up of international researchers, experts in enzymology, microbiology, biomarine sciences, cell therapy and regenerative medicine, and of pharmaceutical marketing professionals.
Abiel produces and commercializes recombinant collagenases. Collagenases are enzymes able to digest the extracellular matrix, where cells are embedded. Cells like stem cells, once ‘extracted’ from the matrix, can be used for therapeutic applications. Common collagenases have natural origin and not ensure either to obtain a consistent number of cells or reproducible results.
Abiel’s Recombinant collagenases are the first collagenases synthesized in lab applying a patented genetic engineering technology, and they show advantages as compared to common collagenases in terms of:
- Higher stability
- Control of the final composition
- Lot-to-lot consistency
- Absence of endotoxins
- Price competitiveness
Collagenases find application in regenerative medicine and cell therapy, further than in biopharmaceutics and cosmeceutics applications. In regenerative medicine, they are used to extract stem cells and primary cells (like hepatocytes, chondrocytes, osteoblasts) or to isolate pancreatic islets that produce insulin. These cells are then used for therapeutic purposes to treat diabetes, cancer, osteoarthritis, etc…
- Production of enzymes in fermenter and purification
- Engineering and development of recombinant proteins
- Screening and characterization of lytic enzymes
- In vitro test to assess enzymatic procedures toxicity
- Murine models for tissue dissociation enzymes selection